ライフサイエンスコーパス: renal impairment

1 study arm (all cases and among those without renal impairment).

2 athic changes, low platelet count, and acute renal impairment).

3 management of patients with both cancer and renal impairment.

4 t at the detriment of patients with ESLD and renal impairment.

5 oronary syndrome (NSTE-ACS) in patients with renal impairment.

6 ulation of patients with type 2 diabetes and renal impairment.

7 cular disease, inflammation, thrombosis, and renal impairment.

8 nts with AF are validated but do not include renal impairment.

9 proliferation were significantly enhanced in renal impairment.

10 vascular inflammation and atherosclerosis in renal impairment.

11 n was increased in atherosclerotic mice with renal impairment.

12 in HIV-positive persons without preexisting renal impairment.

13 elderly people with no clinical diagnosis of renal impairment.

14 recommended affect acute rejection rates and renal impairment.

15 e renal impairment compared to those with no renal impairment.

16 ct patient prognosis in patients with MM and renal impairment.

17 mpared with the AF population without severe renal impairment.

18 proportionally suppressed with the degree of renal impairment.

19 s seen in the patient population with severe renal impairment.

20 e deliberately excluded patients with severe renal impairment.

21 sity anticoagulation in patients with severe renal impairment.

22 ion between invasive Moraxella infection and renal impairment.

23 cal appearance, proteinuria, and progressive renal impairment.

24 a high dose, and subgroups of patients with renal impairment.

25 yocardial injury, myocardial infarction, and renal impairment.

26 thic hemolytic anemia, thrombocytopenia, and renal impairment.

27 midronate dose in patients with pre-existing renal impairment.

28 buminuria and 1,449 (29%) of 5,032 developed renal impairment.

29 veloped albuminuria and nearly 30% developed renal impairment.

30 eloped albuminuria and 1,132 (28%) developed renal impairment.

31 herosclerosis, even in the setting of subtle renal impairment.

32 racial disparities at the highest levels of renal impairment.

33 n patients with type 2 diabetes and moderate renal impairment.

34 atinine clearance frequently fails to detect renal impairment.

35 d event, infection, diabetes, malignancy, or renal impairment.

36 or patients with heart failure, diabetes, or renal impairment.

37 after liver transplantation, but they cause renal impairment.

38 should be used with caution in patients with renal impairment.

39 ut ethnic/racial disparities for early-onset renal impairment.

40 in which both groups had a similar level of renal impairment.

41 21 of whom had HIVN with varying degrees of renal impairment.

42 led five loci involved in the development of renal impairment.

43 scintigraphic parameters and the severity of renal impairment.

44 ole of the tubulointerstitium in the role of renal impairment.

45 n, and had a lower hematocrit value and more renal impairment.

46 red in patients with moderate, but not mild, renal impairment.

47 f of the genetic variation in key indices of renal impairment.

48 agnosed with essential hypertension and mild renal impairment.

49 gulation therapy, and substantial hepatic or renal impairment.

50 s trended lower at baseline and 3 hours with renal impairment.

51 Of 4726 patients identified, 904 (19%) had renal impairment.

52 erythematosus that can lead to irreversible renal impairment.

53 effect of TAVR among patients with baseline renal impairment.

54 er aortic valve replacement in patients with renal impairment.

55 an who presented with nephrotic syndrome and renal impairment.

56 , hypertension, hyperlipidemia, smoking, and renal impairment.

57 patients with atrial fibrillation (AF) with renal impairment.

58 I or IV was seen in 5 patients with baseline renal impairment.

59 clinical indications or severity of baseline renal impairment.

60 d introduction of sirolimus in patients with renal impairment.

61 mg every 48 hours in patients with moderate renal impairment.

62 e (22.1%), significant bleeding (13.9%), and renal impairment (11.9%) were the most common.

63 APACHE II score >=15, 24.7% moderate/severe renal impairment, 42.9% were >=65 years old, and 66.1% w

64 ort including patients with risk factors for renal impairment a marked decline in renal function was

65 ere presence of CRAB (C=calcium elevation; R=renal impairment; A=anaemia; B=bone involvement) criteri

66 icant, independent predictors for death were renal impairment, acidosis, parasitemia, and plasma PfHR

67 independent predictors of AKI were baseline renal impairment (adjusted hazard ratio, 4.15; 95% confi

68 infection was independently associated with renal impairment (adjusted odds ratio [aOR] = 2.1; 95% c

69 Subclinical renal impairment affects approximately 50% of scleroderm

70 NSF develops in patients with renal impairment after exposure to gadopentetate dimeglu

71 account for worse outcomes in patients with renal impairment after MI.

72 ribute to the increased risk associated with renal impairment after myocardial infarction (MI).

73 infection was independently associated with renal impairment, albuminuria, and proximal renal tubula

74 In bivariate analyses, the odds of renal impairment among black women was estimated to be 2

75 The frequency of baseline renal impairment among high-risk and inoperable patients

76 nt for the association between ethnicity and renal impairment among men.

77 ow-up > or =1 year, 38% of patients with any renal impairment and 51% with moderate to severe impairm

78 ng the pathophysiologic interactions between renal impairment and brain function is important in orde

79 While the association between renal impairment and cardiovascular disease (CVD) is wel

80 Irrespective of diagnosis, patients with renal impairment and elevated cardiac troponin concentra

81 ffected by HFD, in marked contrast to severe renal impairment and glomerulopathy in the wild-type mic

82 d 0.78 million women with moderate or severe renal impairment and gout.

83 Renal impairment and high model of end-stage liver disea

84 -3 concentrations increased with progressive renal impairment and independently associated with cardi

85 has not been studied in patients with severe renal impairment and is not recommended in this setting.

86 ke (IS)/thromboembolism (TE) associated with renal impairment and its incremental predictive value ov

87 ten progress from haematuria to proteinuria, renal impairment and kidney failure.

88 atients with white-coat hypertension develop renal impairment and left ventricular hypertrophy.

89 udies characterizing the association between renal impairment and mortality in 80,098 hospitalized an

90 to a PK/PD-driven dosing approach, baseline renal impairment and older age strongly predict AKI occu

91 ion with respect to comorbidities, including renal impairment and overall prognosis.

92 EBR/GZR is approved for use in patients with renal impairment and patients on dialysis, but not in th

93 atients are not safe in patients with severe renal impairment and patients on dialysis.

94 In TACO, cardiac or renal impairment and positive fluid balance appear first

95 pressants given as monotherapy, for example, renal impairment and posttransplant lymphoproliferative

96 This deletion attenuated renal impairment and reduced tubular apoptosis in mercur

97 the post-treatment development of persistent renal impairment and the 60-day rate of death or readmis

98 kinetics of imatinib in cancer patients with renal impairment and to develop dosing guidelines for im

99 erated doses of oxaliplatin in patients with renal impairment and to develop formal guidelines for ox

100 ation between race/ethnicity and early-onset renal impairment and to identify other risk factors that

101 d perfusion is contraindicated (eg, allergy, renal impairment) and holds promise in differentiating t

102 bidities (notably cardiovascular disease and renal impairment) and the need to avoid hypoglycaemia, w

103 A total of 63% of patients had any renal impairment, and 29% had moderate to severe impairm

104 t of necrotizing crescentic GN, albuminuria, renal impairment, and accumulation of CD4(+) T cells and

105 were independently associated with ascites, renal impairment, and bacterial infection.

106 Acidosis, cerebral involvement, renal impairment, and chronic illness are key independen

107 ables such as systemic ventricular function, renal impairment, and diuretic therapy (adjusted hazard

108 dose adjustments for sex, age, or hepatic or renal impairment, and has a safety profile similar to th

109 recipients without causing severe acidosis, renal impairment, and hemodynamic instability.

110 cannulation methods, hemoglobin level, coma, renal impairment, and hepatic impairment were not associ

111 ion, left ventricular diastolic dysfunction, renal impairment, and leg ulcers, were associated with e

112 sulodexide in patients with type 2 diabetes, renal impairment, and macroalbuminuria.

113 adjustment is not required in patients with renal impairment, and monitoring can be less intense bec

114 HD had more heart failure, coronary disease, renal impairment, and persistent atrial fibrillation.

115 known about the effects of milder degrees of renal impairment, and previous studies have relied on le

116 sulodexide in patients with type 2 diabetes, renal impairment, and significant proteinuria (>900 mg/d

117 od from SSc-related gastroesophageal reflux, renal impairment, and skin fibrosis.

118 be challenging to interpret in patients with renal impairment, and the effectiveness of testing in th

119 ly restricted to patients with pretransplant renal impairment, and this strategy could result into wo

120 % confidence interval [CI]: 0.75 to 1.49 for renal impairment; and hazard ratio: 1.09; 95% CI: 0.84 t

121 /m(2) or higher; severe cardiac, hepatic, or renal impairment; and more than two severe hypoglycaemic

122 00-1.01, increase per 10x9 decrease), severe renal impairment (aOR 5.14, 95%CI 2.65-9.97), and low al

123 Cardiovascular disease and renal impairment are common in cirrhotic transplant cand

124 Moderate and moderately severe renal impairment are common in patients with heart failu

125 onset of dementia in patients with moderate renal impairment are needed.

126 n race/ethnicity related risk of early-onset renal impairment are particularly large among men and ar

127 odystrophy, from developing in patients with renal impairment are reviewed.

128 Renal impairment as assessed by serum creatinine was mor

129 diac troponin identified fewer patients with renal impairment as low risk and more as high risk, but

130 presentation identified 17% of patients with renal impairment as low risk for the primary outcome (ne

131 re the role of toxic solutes retained due to renal impairment as mediators of cardiovascular risk.

132 ir impact on UPV and the other parameters of renal impairment, as well as an interaction with BP.

133 er transplantation were associated with less renal impairment at 1 year (RR = 0.51 [0.38-0.69]), with

134 the 99th centile were lower in patients with renal impairment at 50.0% (95% CI, 45.2%-54.8%) and 70.9

135 for age >50 years (HR 3.49, P = 0.087), mild renal impairment at baseline (HR 4.49, P = 0.073), and h

136 choosing telavancin in patients with severe renal impairment at baseline.

137 ty rates in patients with moderate to severe renal impairment at baseline; however, on subsequent ana

138 rity of histopathologic lesions, severity of renal impairment at diagnosis, and hypertension.

139 Fifty-two (2.7%) women and 39 (2.4%) men had renal impairment at the year 15 examination.

140 Familial childhood gout with progressive renal impairment attributable to mutations of the uromod

141 nephrectomized normal littermates to exhibit renal impairment because of the combination of reduced n

142 ence of hypertension, diabetes mellitus, and renal impairment (but had higher prevalence of stroke an

143 Rf-1 strongly affects the risk of renal impairment, but has no significant effect on blood

144 al agents (ARVs) are associated with chronic renal impairment, but the extent of such adverse events

145 disoproxil fumarate (TDF) has been linked to renal impairment, but the extent to which this impairmen

146 rsus 5% [95% CI: 7.3% to 38%]; P=0.006), and renal impairment by 23% (30% versus 7%; [95% CI: 6.4 to

147 Renal impairment by both creatinine and eGFR definitions

148 Here, we describe a 40-year-old man with renal impairment, cardiac and GI symptoms, and periphera

149 rtension [HTN], hyperlipidemia, alcohol use, renal impairment, chronic kidney disease [CKD], and oste

150 ia (microalbuminuria or macroalbuminuria) or renal impairment (Cockcroft-Gault estimated creatinine c

151 , 22.0) respectively among those with severe renal impairment compared to those with no renal impairm

152 Events were more common in patients with renal impairment compared with those without (48% versus

153 hepatorenal syndrome (HRS2) is a functional renal impairment complicating end-stage liver disease.

154 Renal impairment confers an increased risk of stroke, bl

155 ll-cause mortality risks associated with any renal impairment (creatinine >1.0 mg/dl, creatinine clea

156 3 patients with type 2 diabetes mellitus and renal impairment (creatinine 1.5-3 mg/dL) who were candi

157 Subjects with preexisting renal impairment (creatinine clearance, 40-60 mL/minute)

158 The study population was stratified by renal impairment defined by serum creatinine level and b

159 ease (with or without cirrhosis) with severe renal impairment, dependence on dialysis, or both.

160 Persistent renal impairment developed in 15.0% of patients in the r

161 , with higher rates of hypercholesterolemia, renal impairment, diabetes, and multivessel and left mai

162 r disease, hypertension, raised cholesterol, renal impairment, diabetes, obesity, hypothyroidism, hyp

163 After adjustment for CHADS(2) risk factors, renal impairment did not significantly increase the risk

164 age, a preexisting do-not-resuscitate order, renal impairment, disseminated cancer, preoperative seps

165 cardiac troponin I in those with and without renal impairment (estimated glomerular filtration rate <

166 This substudy of patients with baseline renal impairment (estimated glomerular filtration rate [

167 We compared prevalence of renal impairment (estimated glomerular filtration rate [

168 s zanamivir 600 mg twice daily, adjusted for renal impairment, for up to 10 days.

169 Increasing heart rate and chronic renal impairment further predicted mortality.

170 ry amyloidosis that typically manifests with renal impairment, gastrointestinal (GI) symptoms, and si

171 Fifty-one patients (CNI group) with renal impairment (GFR < or =50 mL/min) maintained on CNI

172 group) of whom 58 (group A) had CNI-induced renal impairment (glomerular filtration rate [GFR] <50 m

173 ere, 29.1% with moderate, and 9.2% with mild renal impairment had dabigatran levels >20 ng/ml compare

174 of renal function, but patients with severe renal impairment had higher 30- and 90-day mortality rat

175 Renal impairment has not been reported as a safety signa

176 BG) surgery, the impact of lesser degrees of renal impairment has not been well studied.

177 Renal impairment (hazard ratio, 2.07; 95% confidence int

178 -generated random sequence and stratified by renal impairment, HbA1c, and background antidiabetes med

179 sed age (HR 1.63), U.S. residency (HR 1.61), renal impairment (HR 1.50), stroke/transient ischemic at

180 sex (HR, 1.70; 95% CI, 1.03-2.80; P=0.036), renal impairment (HR, 2.12; 95% CI, 1.20-3.73; P=0.010),

181 , GI disease (HR, 7.3; 95% CI, 3.6 to 14.8), renal impairment (HR, 8.3; 95% CI, 3.0 to 23.2), neurolo

182 nce interval [CI]: 1.59 to 2.77; p < 0.001); renal impairment (HR: 1.98; 95% CI: 1.42 to 2.76; p < 0.

183 erious angioedema but lower proportions with renal impairment, hyperkalemia, and cough than the enala

184 d odds ratios associated with severe to mild renal impairment, ie.

185 n 43.7% of patients, including CTCAE grade 1 renal impairment in 25.0% and CTCAE grade 2 in 18.8%.

186 patients who had renal revascularisation for renal impairment in a defined geographical area (West of

187 reduced the rate of new-onset or progressive renal impairment in comparison with placebo.

188 We estimated the prevalence of renal impairment in heart failure (HF) patients and the

189 ase, it is unclear whether the prognosis for renal impairment in HF patients differs by race.

190 Renal impairment in HF patients is associated with exces

191 r use were independent predictors of chronic renal impairment in HIV-positive persons without preexis

192 Urinary creatinine clearance underestimated renal impairment in one patient out of two; the bias of

193 ch is significantly related to the degree of renal impairment in patients.

194 Data on bone health and renal impairment in people with human immunodeficiency v

195 established and novel biologic mechanisms of renal impairment in renal diseases.

196 The mechanisms and significance of chronic renal impairment in scleroderma need to be better define

197 ys is a marker for progression of CKD in the Renal Impairment in Secondary Care (RIISC) cohort, a pro

198 n dialysis or with a kidney transplant): (1) Renal Impairment in Secondary Care (RIISC, Queen Elizabe

199 ascular events/procedures and development of renal impairment in the CAFE cohort (unadjusted, P<0.000

200 considered in the differential diagnosis of renal impairment in these patients.

201 xtramedullary involvement, and patients with renal impairment, including patients with renal failure

202 mpared with normal renal function, even mild renal impairment increased the 10-yr risk for mortality

203 Renal impairment increases the risk of stroke and bleedi

204 , pain, urinary tract obstruction with acute renal impairment, infection, procedure-related illness,

205 Severe renal impairment influences the allocation of chemothera

206 Pretransplant renal impairment is a predictor of cardiac event after l

207 Chronic renal impairment is an emerging problem in the managemen

208 Renal impairment is an emerging prognostic indicator in

209 ents with and without renal dysfunction, yet renal impairment is an important determinant of the prov

210 Although renal impairment is associated with accelerated cerebrov

211 Renal impairment is associated with adverse cardiovascul

212 Renal impairment is associated with an increased risk of

213 this study was to determine whether moderate renal impairment is associated with incident dementia am

214 Renal impairment is common among HF patients and confers

215 Renal impairment is highly prevalent among patients with

216 w atherosclerotic inflammation is altered in renal impairment is incompletely understood.

217 isks, but the influence of milder degrees of renal impairment is less well defined.

218 0 mg every 48 hours for adults with moderate renal impairment is often confusing and inconvenient.

219 min B-12 deficiency in a population in which renal impairment is prevalent.

220 isease (CKD), contrast media compatible with renal impairment is sorely needed.

221 use of SOF among HCV-positive patients with renal impairment, is effective and safe.

222 dities, such as impaired glucose metabolism, renal impairment, left ventricular hypertrophy, heart fa

223 e often older and have a higher incidence of renal impairment, may be better able to tolerate MPDL328

224 although it suggests that patients with less renal impairment might benefit.

225 Severe renal impairment more than doubled the risk for mortalit

226 Renal impairment (n=454 vs 317), hypotension (203 vs 145

227 acute rejection [n = 957] and two trials for renal impairment [n = 712]) showed that "reduced tacroli

228 patients with moderate or moderately severe renal impairment, no difference in adverse events compar

229 Patients with renal impairment, obesity, or those who are critically i

230 consecutive liver transplant candidates with renal impairment of unclear etiology referred to determi

231 17a(-/-) bone marrow abolished the effect of renal impairment on aortic CD11b(+) myeloid cell accumul

232 the outcome in patients who received MMF for renal impairment on tacrolimus-based immunosuppression.

233 acute decompensated heart failure (ADHF) and renal impairment or diuretic resistance.

234 ated pulmonary capillary wedge pressure, and renal impairment or substantial diuretic requirement des

235 ent options for post-LT patients with severe renal impairment or who are on dialysis, nor do publishe

236 ncrease in base deficit [95% CI 1.93-2.28]), renal impairment (OR 1.71 for a 2-fold increase in blood

237 mic outcomes (myocardial infarction, stroke, renal impairment, or failure) were prespecified as copri

238 ction, recurrence of autoimmune process(es), renal impairment, or the concomitant presence of other m

239 ssess the associations between the composite renal impairment outcomes and the combination ADM (antid

240 75 patients had intervention for renal impairment over 15 years (68 endovascular, 7 open)

241 The incremental predictive value of renal impairment over CHADS(2) and CHA(2)DS(2)-VASc were

242 97.5%-99.9%), in comparison with 56% without renal impairment (P<0.001) with similar performance (neg

243 n patients with type 2 diabetes and moderate renal impairment, potentially providing a new treatment

244 ores did not influence likelihood of PTx and renal impairment predicted against PTx (OR 0.35, P < 0.0

245 A pretransplant score comprising renal impairment, prolonged QTc interval, and age older

246 patients with type 2 diabetes without overt renal impairment, raised ACR is associated with higher A

247 Moderate renal impairment, reflected by a higher SCr, is associat

248 essed in the kidney, further improves cardio-renal impairment remains unknown.

249 Among 65 patients treated for renal impairment, renal function improved in 20 (30.8%),

250 The rates of hyperkalemia, hypotension, and renal impairment/renal failure were higher in the aliski

251 cy and safety of MMF in patients with severe renal impairment requires further investigation.

252 Grade 1 and 2 renal impairment, respectively, were present in 37.5% an

253 Type 2 diabetes is commonly associated with renal impairment, restricting treatment options.

254 athogenesis of multiple myeloma (MM) related renal impairment (RI).

255 s and management of multiple myeloma-related renal impairment (RI).

256 patients with type 2 diabetes without overt renal impairment (serum creatinine <150 micromol/L).

257 Neurological and renal impairments (serum creatinine, 0.87+/-0.20; median

258 isk factors for osteonecrosis of the jaw and renal impairment should be assessed, and any pending den

259 but not recommended for patients with severe renal impairment (SRI, i.e. creatinine clearance < 30ml/

260 elevated total cholesterol, type 2 diabetes, renal impairment (stage 4 chronic kidney disease), and h

261 For patients with renal impairment, substantial reductions in the use of i

262 rtension, diabetes, prior heart failure, and renal impairment than men.

263 alvage in patients with significant baseline renal impairment that were previously denied interventio

264 5 mg twice daily appeared not to have severe renal impairment, the intended population for this dose.

265 levels within 12 to 24 h is more common with renal impairment, the time to bleeding cessation and the

266 hypotension, leukopenia, metabolic acidosis, renal impairment, thrombocytopenia, and disseminated coa

267 ents with deep vein thrombosis, hepatitis C, renal impairment, thyroid disease, and liver disease fro

268 blood pressure-lowering therapy and without renal impairment to look for metabolites associated with

269 Conclusion In patients with renal impairment undergoing transcatheter aortic valve r

270 When renal impairment was added to existing risk scoring syst

271 Renal impairment was associated with smaller LV and larg

272 Renal impairment was defined as creatinine > or =1.5 mg/

273 nverse of serum creatinine (1/SCr); moderate renal impairment was defined as SCr > or = 1.3 mg/dl for

274 an modify atherosclerosis in a model of mild renal impairment was examined.

275 In Cox regression analysis, pretransplant renal impairment was found to be an independent predicto

276 Baseline renal impairment was frequent among patients who underwe

277 Development of albuminuria or renal impairment was independently associated with incre

278 Renal impairment was not an independent predictor of IS/

279 s with telaprevir (TLV) and boceprevir (BOC) renal impairment was not reported as a relevant adverse

280 Renal impairment was present in 24% (48/202).

281 ess than 85 mm Hg (diastolic) if diabetes or renal impairment was present.

282 hymal stromal cells, postischemic functional renal impairment was reduced, but there was no evidence

283 hite women, and among black men, the odds of renal impairment were 9.0-fold that of white men.

284 ng guidelines for patients with pre-existing renal impairment were added to the zoledronic acid packa

285 th troponin concentrations >99th centile and renal impairment were at greater risk of subsequent myoc

286 Patients with severe renal impairment were excluded from the non-VKA oral ant

287 ad severe congestive heart failure or severe renal impairment were excluded.

288 Additional independent risk factors for renal impairment were female sex, decreased waist circum

289 OR: 0.18, 95% CI: 0.04 to 0.75; P=0.006) and renal impairment were independent of other covariables.

290 ailure Assessment (SOFA), score and baseline renal impairment were significantly associated with AKI.

291 d physician diagnosis of gout and degrees of renal impairment were the primary focus of the present a

292 utcomes at 1 year, and even mild or moderate renal impairments were associated with an increased risk

293 cretion and plasma NOx levels (corrected for renal impairment) were inversely related to disease seve

294 Independent risk factors of IS/TE (including renal impairment) were investigated in Cox regression mo

295 kalemia (K+>7.0 meq/L) and a mild reversible renal impairment, which were thought to reflect in part

296 iopathic osteoporosis (without indication of renal impairment), who received MRI 8 months prior to bi

297 A pathophysiology that links renal impairment with cardiovascular risk has long been

298 els were used to estimate the association of renal impairment with incident dementia.

299 e first month was positively correlated with renal impairment within 1 year (r = 0.73; p = 0.003), bu

300 macokinetic data showed dose adjustments for renal impairment yielded similar zanamivir exposures.